Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

10.13 UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma Inc ADR

< Previous 1 2 3 4 5 6 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Why Shares of Ambrx Biopharma Soared This Week
A big buy by an asset manager spurred interest in the biotech stock. 
Via The Motley Fool
Around $19M Bet On Westrock Coffee? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Where Ambrx Biopharma Stands With Analysts
Via Benzinga
Expert Ratings for Ambrx Biopharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Ambrx Biopharma
Via Benzinga
Why Shares of Ambrx Biopharma Jumped This Week
The company reported data on its clinical programs at two conferences this week. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
Unique ADC Constructs Boost Ambrx Biopharma's Profile: Analyst Sees Optimistic Outlook
RBC Capital Markets initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) With an Outperform rating and a  
Via Benzinga
Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Ambrx Biopharma's Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Why Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
$59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Over $25M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
7 Cheap Stocks That Are Worth Your Attention
Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field. 
Via InvestorPlace
7 Risky Stocks That Are Worth the Stretch
If you're going to invest in risky stocks, it's important for you to first understand your risk tolerance. These names will get you started. 
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
Ambrx Raises $78 Million and Completes its ATM Program
From Ambrx, Inc.
Via Business Wire
Week In Review: Sino Biopharma Acquires F-Star For $161 Million After US Approval
Sino Biopharma was approved to close its $161 million all-cash acquisition of F-Star. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on... 
Via Talk Markets
Why Shares of Ambrx Biopharma Fell Tuesday
After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction. 
Via The Motley Fool
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.